Muscular Dystrophy Association Conference 2026 (MDA)

Back

Zeleciment Rostudirsen Significantly Increased Dystrophin Protein Levels and Led to Functional Improvement in Clinical Measures in the DELIVER Trial (presentation)

Zeleciment Rostudirsen Significantly Increased Dystrophin Protein Levels and Led to Functional Improvement in Clinical Measures in the DELIVER Trial (poster)

Zeleciment Rostudirsen Significantly Increased Dystrophin Protein Levels and Led to Functional Improvement in Clinical Measures in the DELIVER Trial (supplemental data)

Zeleciment Rostudirsen Led to Trends in Long-term Improvement in Clinical Outcomes Including Cardiopulmonary Function: Additional Data from DELIVER (poster)

A Global Phase 3 Trial Assessing the Efficacy and Safety of Z-basivarsen in Myotonic Dystrophy Type 1 (presentation)

A Global Phase 3 Trial Assessing the Efficacy and Safety of Z-basivarsen in Myotonic Dystrophy Type 1 (poster)

Zeleciment Basivarsen Targets the Underlying Cause of DM1 to Enable Functional Improvement in the Phase 1/2 ACHIEVE Trial (poster)

Zeleciment Basivarsen Targets the Underlying Cause of DM1 to Enable Functional Improvement in the Phase 1/2 ACHIEVE Trial (supplemental data)

DYNE-401 Demonstrates Potential to Address Pompe Disease With Low and Infrequent Dosing (presentation)

DYNE-401 Demonstrates Potential to Address Pompe Disease With Low and Infrequent Dosing (poster)